Результати пошуку - Brendon L. Neuen

Уточнити результати
  1. 1
    Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities

    Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities за авторством Kris Vijay, Brendon L. Neuen, Edgar V. Lerma

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    Empagliflozin in Patients with Chronic Kidney Disease

    Empagliflozin in Patients with Chronic Kidney Disease за авторством Brendon L. Neuen, Robert A. Fletcher, Hiddo J.L. Heerspink

    Опубліковано 2023
    Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:
  3. 3
    Chronic kidney disease and the global NCDs agenda

    Chronic kidney disease and the global NCDs agenda за авторством Brendon L. Neuen, Steven J. Chadban, Alessandro Demaio, David W. Johnson, Vlado Perkovic

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Editorial
    Додати у Вибране
    Збережено в:
  4. 4
    Chronic kidney disease

    Chronic kidney disease за авторством Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic

    Опубліковано 2021
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  5. 5
    Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials

    Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials за авторством Edward W. Webster, Adam Perkovic, Brendon L. Neuen, Katherine R. Tuttle, Vlado Perkovic

    Опубліковано 2025
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  6. 6
    Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review

    Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review за авторством Brendon L. Neuen, Ronny Gunnarsson, Angela C Webster, Richard Baer, Jonathan Golledge, Murty L. Mantha

    Опубліковано 2014
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  7. 7
    Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients

    Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients за авторством Brendon L. Neuen, Nicole Leather, A.M. Greenwood, Ronny Gunnarsson, Yeoungjee Cho, Murty L. Mantha

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review

    SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review за авторством Merlin C. Thomas, Brendon L. Neuen, Stephen M. Twigg, Mark E. Cooper, Sunil V. Badve

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  9. 9
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes за авторством Jingwei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L. Neuen, Clare Arnott, Robin Simpson, Richard Oh, Kenneth W. Mahaffey, Hiddo J.L. Heerspink

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis... за авторством Tadashi Toyama, Brendon L. Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg Jardine, Hiddo J.L. Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada, Vlado Perkovic

    Опубліковано 2019
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  11. 11
    Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

    Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials за авторством Sheldon W. Tobe, Thomas A. Mavrakanas, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Wally Rapattoni, Fernando G. Ang

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

    Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis за авторством Clare Arnott, Qiang Li, Amy Kang, Brendon L. Neuen, Séverine Bompoint, Carolyn S.P. Lam, Anthony Rodgers, Kenneth W. Mahaffey, Christopher P. Cannon, Vlado Perkovic, Meg Jardine, Bruce Neal

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  13. 13
    Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial

    Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial за авторством Jennifer Barraclough, Jie Yu, Gemma A. Figtree, Vlado Perkovic, Hiddo J.L. Heerspink, Brendon L. Neuen, Christopher P. Cannon, Kenneth W. Mahaffey, Aletta E. Schutte, Bruce Neal, Clare Arnott

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

    Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... за авторством Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol A. Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

    Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program за авторством Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh, Hiddo J.L. Heerspink, Vlado Perkovic

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

    Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program за авторством Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Jaime D. Blais, Qiang Li, Meg Jardine, Vlado Perkovic, David C. Wheeler

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS за авторством Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis за авторством Brendon L. Neuen, Robert A. Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V. Badve, Katherine R. Tuttle, Richard E. Pratley, Hertzel C. Gerstein, Vlado Perkovic, Hiddo J.L. Heerspink

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  19. 19
    The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial

    The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial за авторством Clare Arnott, Yuli Huang, Brendon L. Neuen, Gian Luca Di Tanna, Christopher P. Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey, Bruce Neal

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis за авторством Brendon L. Neuen, T. Kue Young, Hiddo J.L. Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W. Mahaffey, David M. Charytan, David C. Wheeler, Clare Arnott, Séverine Bompoint, Adeera Levin, Meg Jardine

    Опубліковано 2019
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: